HTLV-I/II PCR

HTLV-I/II PCR.

Molecular Detection

Human T-lymphotropic virus (HTLV)

National Laboratory for HIV Reference Services

• Adult T-cell leukemia/lymphoma (ATLL)

EDTA whole blood; 5mL (minimum 2mL with the exception of babies).  Contact NLHRS for specimens other than those listed.  

Note: Specimens categorized as “other” are not subject to accreditation by the Standards Council of Canada for the specific scopes of accreditation published on www.scc.ca.

See specimen above.

Ambient temperature (received within 48 hours of collection).

Shipping of specimens shall be done by a TDG certified individual in accordance with TDG regulations. For additional information regarding classification of specimens for the purposes of shipping, consult either Part 2 Appendix 3 of the TDG Regulations or section 3.6.2 of the IATA Dangerous Goods Regulations as applicable.

Please provide risk factors.

NLHRS HTLV I/II Requisition: PCR, Serology & Viral Load

• See attached NLHRS Submission Guidelines.
• Molecular samples may be screened by our serological testing algorithm.

Testing is performed, in whole or in part, using a lab-developed test which has not been fully validated/verified due to a lack of well-characterized panel.

Varies for each test method, contact NLHRS for further information.

Varies for each test method, contact NLHRS for further information.

1. Standard Council of Canada. SCC accredits first medical laboratory under new national program.  2008. http://www.scc.ca/en/news-events/news/2008/scc-accredits-first-medical-laboratory-under-new-national-program
2. S.Lavoie, D. Caswell, M.J. Gill, K. Kadkhoda, C.L Charlton, P.N. Levett, T.Hatchette, R. Garceau, J. Maregmen, T. Mazzulli, R. Needle, K. Kadivar, J. Kim. Heterophilic interference in specimens yielding false-reactive results on the Abbott 4th generation ARCHITECT HIV Ag/Ab Combo Assay. Journal of Clinical Virology. 2018;104: 23-28
3. Malloch L, Kadivar K, Putz J, Levett PN, Tang J, Hatchette TF, Kadkhoda K, Ng D, Ho J, Kim J. Comparative Evaluation of the Bio-Rad Geenius HIV-1/2 Confirmatory Assay and the Bio-Rad Multispot HIV-1/2 Rapid Test as an Alternative Differentiation Assay for CLSI M53 Algorithm-I. Journal of Clinical Virology. 2013;58, Supplement 1(0):e85-e91. http://www.sciencedirect.com/science/article/pii/S1386653213003326
4. Kadivar K, Malloch L, Adonsou-Hoyi Y, Ng D, Lavoie S, Pulido K, Kim J. Would CLSI M53-A Have Helped in the Diagnosis of HIV in Canada? Results of the Performance of Canadian Laboratories Participating in a Recent NLHRS Proficiency Testing Panel Containing HIV-1 Antigen Positive (Antibody Negative) and HIV-2 Samples. Journal of Clinical Virology. 2013;58(1):303-305. http://www.sciencedirect.com/science/article/pii/S1386653213001303

Pathogen Safety Data Sheets: Infectious Substances – Human T-lymphotropic virus (HTLV)

Biosafety Directive for Human Immunodeficiency Virus (HIV) and Human T-cell Lymphotropic Virus Type 1 (HTLV-1)